European biotech needs specialized capital and stronger continuity across funding stages to get to the next level, writes ...

Clinical development costs are rising due to the disruption of shipping routes in the Strait of Hormuz, writes Mathini ...

Novo Nordisks Aleksandar Ciric writes that leaders can apply sports principles such as speed of action, clarity, and ...

For US-based cell and gene therapy developers, achieving EU approval isn't simply a matter of transposing an FDA strategy across the Atlantic; it demands a fundamentally different mindset. The EU ...

The growing complexity of trial protocols is increasing the burden of manual data entry, requiring thousands of hours from physicians, nurses, and research coordinators for each study. Fragmented ...

Speed alone no longer guarantees success; here’s what matters most in today’s launch environment. In today’s launch environment, order of entry (OOE) isn’t destiny. Many brands still anchor strategy ...

On this week's episode of the Business of Biotech, Thijs Spoor, CEO at Perspective Therapeutics, a company developing Pb 212 (lead)-based therapeutics, talks about why radiopharmaceuticals are surging ...

Precision is the silent arbiter of success in ophthalmic research, yet ocular endpoints like BCVA and OCT remain frequent failure points due to inconsistent execution. When these specialized ...

Craig Scharton and Hannah Maeda spoke to participants at January’s K.I.N.D Health Innovation CLT Mind Design Thinking Workshop. -Photo from Austin King, MediaCutlet Charlotte’s health innovation ...

North Carolina has earned its place as a global life sciences leader—but maintaining that position will require deliberate action. Leaders from biopharma, economic development, real estate, and ...

Laurie Braxton of FUJIFILM Biotechnologies on a panel at INTERPHEX On the Ground at the FUJIFILM facility in Holly Springs, N.C. -Photo from FUJIFILM Biotechnologies North Carolina’s life sciences ...